Loading...
Loading...
Browse all stories on DeepNewz
VisitHilleVax Shares Plunge 88.6% to $1.60 After Norovirus Vaccine Fails in Mid-Stage Trial
Jul 8, 2024, 01:50 PM
HilleVax reported that its NEST-IN1 Phase 2b clinical study of HIL-214 in infants did not meet its primary or secondary efficacy endpoints. As a result, the company will discontinue further development of HIL-214 in infants. Following this announcement, HilleVax's stock plummeted, dropping 88.6% to $1.60 in premarket trade, with an 86.3% decline premarket. The failed trial aimed to prevent gastroenteritis caused by norovirus, specifically acute gastroenteritis. The significant decline in stock value reflects investor disappointment in the biotech company's sole clinical candidate's failure.
View original story
Markets
No • 50%
Yes • 50%
Official press releases from HilleVax
No • 50%
Yes • 50%
Official acquisition announcements or financial news outlets
Yes • 50%
No • 50%
Publicly available stock market data
$500 million to $1 billion • 25%
Below $100 million • 25%
Above $1 billion • 25%
$100 million to $500 million • 25%
Publicly available financial data
Other • 25%
Company restructuring or layoffs • 25%
New clinical trial for different vaccine • 25%
Partnership with another biotech company • 25%
Official press releases from HilleVax or industry news
Above $5 • 25%
Below $1 • 25%
$1 to $2 • 25%
$2 to $5 • 25%
Publicly available stock market data